BTVPUR AlSap 1

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

antigena serotipa-1 virusa bolezni modrikastega jezika

Available from:

Merial

ATC code:

QI04AA02

INN (International Name):

bluetongue-virus serotype-1 antigen

Therapeutic group:

Sheep; Cattle

Therapeutic area:

Imunologija

Therapeutic indications:

Aktivna imunizacija ovac in goveda za preprečevanje viremije in zmanjšanje kliničnih znakov, ki jih povzroča serotip 1 virusa bolezni modrikastega jezika. Začetek imunosti je bil dokazan tri tedne po osnovnem cepljenju. Trajanje imunitete za govedo in ovce je eno leto po osnovnem cepljenju.

Product summary:

Revision: 4

Authorization status:

Umaknjeno

Authorization date:

2010-12-17

Patient Information leaflet

                                Zdravilo nima veā dovoljenja za promet
15
B. NAVODILO ZA UPORABO
Zdravilo nima veā dovoljenja za promet
16
NAVODILO ZA UPORABO
BTVPUR ALSAP 1 SUSPENZIJA ZA INJICIRANJE ZA OVCE IN GOVEDO
1.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER
IMETNIKA DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVORNEGA ZA
SPROSTITEV SERIJE V EGP, ČE STA RAZLIČNA
Imetnik dovoljenja za promet z zdravilom:
MERIAL
29 avenue Tony Garnier
69007 Lyon,
Francija
Izdelovalec, odgovoren za sprostitev serije:
MERIAL
Laboratory of Lyon Porte des Alpes
Rue de l’Aviation,
69800 Saint-Priest
Francija
2.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
BTVPUR AlSap 1 suspenzija za injiciranje za ovce in govedo
3.
NAVEDBA ZDRAVILNE(IH) UČINKOVIN(E) IN DRUGEIH SESTAVIN
Vsak odmerek (1 ml) cepiva (homogena mlečno bela suspenzija) vsebuje:
Zdravilna učinkovina:
Virus bolezni modrikastega jezika, serotip 1, inaktiviran
................................... ≥ 1,9 log
10
pikslov*
(
*
)
Vsebnost antigena (VP2 protein) z imonuloškimi metodami
Dodatki:
.Al
3+
(kot hidroksid)
...................................................................................................................
2.7 mg
.Saponin
..................................................................................................................................
30 HE**
(
**
)
Hemolizne enote
4.
INDIKACIJA(E)
Aktivna imunizacija ovc in goveda proti virusu bolezni modrikastega
jezika, serotip 1, za preprečitev
viremije* in zmanjšanje kliničnih znakov.
*(pod stopnjo detekcije z validirano metodo RT-PCR pri 3.,68 log
10
RNA kopijah/ml, ni
prenosa virusa)
Imunost nastopi 3 tedne po osnovnem cepljenju.
Trajanje imunosti pri ovcah in govedu je 1 leto po osnovnem cepljenju.
5.
KONTRAINDIKACIJE
Jih ni.
Zdravilo nima veā dovoljenja za promet
17
6.
NEŽELENI UČINKI
V zelo redkih primerih se lahko po cepljenju na mestu dajanja pojavi
prehodna manjša
lokalizirana oteklina (največ 32 cm
2
pri govedu in 24 cm
2
pri ovcah), ki se občutno zmanjša v največ 35 dneh (≤ 1 cm
2
).
V zel
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                Zdravilo nima veā dovoljenja za promet
1
DODATEK I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 17-05-2018
Summary of Product characteristics Summary of Product characteristics Bulgarian 17-05-2018
Public Assessment Report Public Assessment Report Bulgarian 17-05-2018
Patient Information leaflet Patient Information leaflet Spanish 17-05-2018
Public Assessment Report Public Assessment Report Spanish 17-05-2018
Patient Information leaflet Patient Information leaflet Czech 17-05-2018
Public Assessment Report Public Assessment Report Czech 17-05-2018
Patient Information leaflet Patient Information leaflet Danish 17-05-2018
Public Assessment Report Public Assessment Report Danish 17-05-2018
Patient Information leaflet Patient Information leaflet German 17-05-2018
Public Assessment Report Public Assessment Report German 17-05-2018
Patient Information leaflet Patient Information leaflet Estonian 17-05-2018
Public Assessment Report Public Assessment Report Estonian 17-05-2018
Patient Information leaflet Patient Information leaflet Greek 17-05-2018
Public Assessment Report Public Assessment Report Greek 17-05-2018
Patient Information leaflet Patient Information leaflet English 17-05-2018
Public Assessment Report Public Assessment Report English 17-05-2018
Patient Information leaflet Patient Information leaflet French 17-05-2018
Public Assessment Report Public Assessment Report French 17-05-2018
Patient Information leaflet Patient Information leaflet Italian 17-05-2018
Public Assessment Report Public Assessment Report Italian 17-05-2018
Patient Information leaflet Patient Information leaflet Latvian 17-05-2018
Public Assessment Report Public Assessment Report Latvian 17-05-2018
Patient Information leaflet Patient Information leaflet Lithuanian 17-05-2018
Summary of Product characteristics Summary of Product characteristics Lithuanian 17-05-2018
Public Assessment Report Public Assessment Report Lithuanian 17-05-2018
Patient Information leaflet Patient Information leaflet Hungarian 17-05-2018
Summary of Product characteristics Summary of Product characteristics Hungarian 17-05-2018
Public Assessment Report Public Assessment Report Hungarian 17-05-2018
Patient Information leaflet Patient Information leaflet Maltese 17-05-2018
Public Assessment Report Public Assessment Report Maltese 17-05-2018
Patient Information leaflet Patient Information leaflet Dutch 17-05-2018
Public Assessment Report Public Assessment Report Dutch 17-05-2018
Patient Information leaflet Patient Information leaflet Polish 17-05-2018
Public Assessment Report Public Assessment Report Polish 17-05-2018
Patient Information leaflet Patient Information leaflet Portuguese 17-05-2018
Summary of Product characteristics Summary of Product characteristics Portuguese 17-05-2018
Public Assessment Report Public Assessment Report Portuguese 17-05-2018
Patient Information leaflet Patient Information leaflet Romanian 17-05-2018
Public Assessment Report Public Assessment Report Romanian 17-05-2018
Patient Information leaflet Patient Information leaflet Slovak 17-05-2018
Public Assessment Report Public Assessment Report Slovak 17-05-2018
Patient Information leaflet Patient Information leaflet Finnish 17-05-2018
Public Assessment Report Public Assessment Report Finnish 17-05-2018
Patient Information leaflet Patient Information leaflet Swedish 17-05-2018
Public Assessment Report Public Assessment Report Swedish 17-05-2018
Patient Information leaflet Patient Information leaflet Norwegian 17-05-2018
Summary of Product characteristics Summary of Product characteristics Norwegian 17-05-2018
Patient Information leaflet Patient Information leaflet Icelandic 17-05-2018
Summary of Product characteristics Summary of Product characteristics Icelandic 17-05-2018
Patient Information leaflet Patient Information leaflet Croatian 17-05-2018

View documents history